LeonaBio Analyst Price Targets - Benzinga

LeonaBio Inc

LONANASDAQ

Trade with Public

Trade with Public

$4.38

0.8122.69%

Ult. Agg.: Oct 2, 7:52 AM

$4.40

0.8323.25%

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Rapporto azionario

LeonaBio Analyst Price Targets - Benzinga

LeonaBio Analyst Price Targets

Wall Street analyst price targets and consensus rating for LeonaBio (LONA).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

1S.Buy

2Buy

Consensus RatingOverweight# Analysts3Avg. Consensus PT$17Upside to Avg. PT+293.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 19, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$16→$15
Aug 17, 2026	Citizens	Jason N. Butler	PT Cut	Market Outperform	$18→$17
Jul 30, 2026	Citizens	Jason N. Butler	Upgrade	Market Perform→Market Outperform	$18
May 27, 2026	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$20
Feb 19, 2026	Mizuho	Graig Suvannavejh	Upgrade	Neutral→Outperform	$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15

Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers the price target from $16 to $15.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17

Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $18 to $17.

Benzinga Newsdesk

PRO
Citizens Upgrades LeonaBio to Market Outperform, Announces $18 Price Target

Citizens analyst Jason N. Butler upgrades LeonaBio (NASDAQ:LONA) from Market Perform to Market Outperform and announces $18 price target.

Benzinga Newsdesk

PRO
Piper Sandler Initiates Coverage On LeonaBio with Overweight Rating, Announces Price Target of $20

Piper Sandler analyst Kelsey Goodwin initiates coverage on LeonaBio (NASDAQ:LONA) with a Overweight rating and announces Price Target of $20.

Benzinga Newsdesk